Delcath Systems (DCTH) Aperçu de l'action
Delcath Systems, Inc. est une société d'oncologie interventionnelle qui se concentre sur le traitement des cancers du foie primaires et métastatiques aux États-Unis et en Europe. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 4/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
DCTH Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Delcath Systems, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$15.91 |
| Plus haut sur 52 semaines | US$17.42 |
| Plus bas sur 52 semaines | US$8.12 |
| Bêta | 0.57 |
| Variation sur 1 mois | -4.90% |
| Variation sur 3 mois | 34.94% |
| Variation sur 1 an | 46.77% |
| Variation sur 3 ans | 255.13% |
| Variation sur 5 ans | 74.45% |
| Évolution depuis l'introduction en bourse | -99.90% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 21
DCTH: 2026 Spending And Index Additions Will Support Liver Cancer Therapy Adoption
Analysts lifted their fair value estimate for Delcath Systems from $21.33 to $24.00, supported by an improved profit margin outlook and a lower assumed discount rate, even as they anticipate more measured revenue growth and a significantly lower future P/E multiple. What’s in the News for Delcath Systems Delcath Systems raised full year 2026 revenue guidance to a range of $104 million to $108 million, reflecting at least 28% growth in HEPZATO KIT volume over 2025.
Mise à jour du récit • Aug 07
DCTH: MedTech Earnings Catalyst And Trial Progress Will Support Future Upside
Analysts have lifted their fair value estimate for Delcath Systems from $16.00 to $21.00, citing recent Street research that points to a slightly higher $17.00 price target and potential sentiment improvement around upcoming MedTech earnings. What’s in the News for Delcath Systems Delcath Systems raised full year 2026 revenue guidance to a range of US$104 million to US$108 million, tied to an expected 28% growth in HEPZATO KIT volume over 2025.Recent updates
Mise à jour du récit • Aug 21
DCTH: 2026 Spending And Index Additions Will Support Liver Cancer Therapy Adoption
Analysts lifted their fair value estimate for Delcath Systems from $21.33 to $24.00, supported by an improved profit margin outlook and a lower assumed discount rate, even as they anticipate more measured revenue growth and a significantly lower future P/E multiple. What’s in the News for Delcath Systems Delcath Systems raised full year 2026 revenue guidance to a range of $104 million to $108 million, reflecting at least 28% growth in HEPZATO KIT volume over 2025.Mise à jour du récit • Aug 07
DCTH: MedTech Earnings Catalyst And Trial Progress Will Support Future Upside
Analysts have lifted their fair value estimate for Delcath Systems from $16.00 to $21.00, citing recent Street research that points to a slightly higher $17.00 price target and potential sentiment improvement around upcoming MedTech earnings. What’s in the News for Delcath Systems Delcath Systems raised full year 2026 revenue guidance to a range of US$104 million to US$108 million, tied to an expected 28% growth in HEPZATO KIT volume over 2025.Mise à jour du récit • Jun 14
DCTH: Guideline Endorsements And Liver Cancer Data Will Support Future Upside
Analysts are keeping Delcath Systems' fair value estimate steady at $16.00, citing largely unchanged assumptions for discount rate, revenue growth, profit margin and future P/E that together support maintaining the prior price target level. What's in the News Two investigator initiated trials using HEPZATO KIT in metastatic melanoma are planned for presentation as abstracts at the 2026 ASCO Annual Meeting in Chicago, highlighting ongoing Phase 2 and Phase 1b/2 studies in uveal and non uveal melanoma involving the liver.Mise à jour du récit • May 31
DCTH: Liver-Directed Cancer Trials And Guideline Endorsements Will Drive Future Upside
Analysts have reduced their price target for Delcath Systems from $18.00 to $16.00 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E now point to slightly more conservative expectations. What's in the News Two investigator-initiated trials-in-progress abstracts on percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT Hepatic Delivery System are scheduled for presentation at the 2026 ASCO Annual Meeting in Chicago.Mise à jour du récit • Apr 30
DCTH: 2026 Spend Increase Will Drive Hepatic Cancer Therapy Adoption
Analysts have trimmed their blended price target on Delcath Systems by about $2 to align with recent Street research that lowered the target to $27, citing updated FY26 sales guidance of at least $100m and sharply higher planned R&D and SG&A spending to support HEPZATO commercial and label expansion efforts. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$27 price target as still reflecting upside potential relative to current trading levels, even after trimming expectations.Mise à jour du récit • Apr 16
DCTH: 2026 Spend Increase Will Support Hepatic Cancer Therapy Expansion
Analysts trimmed their price target on Delcath Systems to $27 from $29, citing updated guidance for at least $100M in FY26 sales and a very large projected increase in R&D and SG&A spending to support the HEPZATO label and commercial expansion. Analyst Commentary Recent commentary focuses on how the updated FY26 sales outlook and higher operating spend could affect the risk and reward profile for Delcath Systems, especially around execution on HEPZATO and future label opportunities.Mise à jour du récit • Apr 02
DCTH: Higher 2026 Spending Will Support Liver Cancer Therapy Expansion
Analysts have trimmed their average price target on Delcath Systems by $2, citing recent FY25 results, updated FY26 sales guidance of at least $100M versus prior consensus of $111M, and expectations for higher R&D and SG&A spending to support HEPZATO growth and label expansion. Analyst Commentary Recent Street commentary on Delcath Systems centers on how near term spending and updated sales guidance could affect the risk and reward profile for shareholders.Mise à jour du récit • Mar 18
DCTH: Higher 2026 Spending Will Support Cancer Therapy Cash Flows And Expansion
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been trimmed by $2 to $27, as analysts factor in the company's FY26 sales guidance of at least $100M, along with sharply higher planned R&D and SG&A spending to support HEPZATO and label expansion. Analyst Commentary Recent research updates on Delcath Systems highlight a mixed reaction to the company’s outlook, with particular attention on FY26 guidance and the spending required to support HEPZATO and label expansion.Mise à jour du récit • Mar 04
DCTH: Higher 2026 Spending Will Support Future Revenue Expansion Potential
Narrative Update on Delcath Systems The analyst price target for Delcath Systems has been reduced by $3 to $27. Analysts point to updated FY26 sales guidance of at least $100M and significantly higher projected R&D and SG&A spending to support HEPZATO growth and label expansion as key factors behind the change.Mise à jour du récit • Feb 18
DCTH: Steadier Cancer Therapy Cash Flows Will Support Future Indication Expansion
Analysts have raised their price target on Delcath Systems by $1 to $29, citing preliminary Q4 results that indicate Hepzato is becoming a more stable revenue contributor, with more predictable quarter-to-quarter trends and cash flow that may support expansion plans. Analyst Commentary Analysts highlighting the new US$29 price target point to Hepzato’s role as a steadier revenue source and to cash flow that may help support future expansion plans.Mise à jour du récit • Feb 04
DCTH: Steadier Liver Cancer Therapy Revenues Will Support Future Indication Expansion
Analysts have nudged their price target on Delcath Systems higher to $29 from $28, pointing to Hepzato's role as a steady revenue contributor with more predictable quarter to quarter variability and cash flow that can support expansion of additional indications. Analyst Commentary Even with the higher price target, not all commentary around Delcath Systems leans positive.Mise à jour du récit • Jan 20
DCTH: Steadier Hepatic Therapy Uptake Will Support Future Expansion Plans
Analysts recently lifted their price target on Delcath Systems to $29 from $28, citing Hepzato's role as a steadier and more predictable contributor to revenue and cash flow. They believe this supports potential expansion plans and informs modest adjustments to growth, margin, and future P/E assumptions.Mise à jour du récit • Jan 06
DCTH: CHOPIN Trial Data Will Support Future Uptake Despite Softer Guidance
Analysts have kept their fair value estimate for Delcath Systems steady at $18.00 while adjusting underlying assumptions, citing mixed reactions to softer Q3 and FY2025 revenue guidance alongside supportive CHOPIN trial data and a range of updated price targets from $20 to $30. Analyst Commentary Street research on Delcath Systems has centered on the tension between supportive CHOPIN trial data and softer near term revenue guidance, with several price target revisions reflecting this mixed setup.Mise à jour du récit • Dec 14
DCTH: CHOPIN Data Expected To Drive Stronger Uptake Despite Near-Term Guidance Reset
Analysts have trimmed their fair value estimate for Delcath Systems to $18.00 from $21.00, reflecting lower near term revenue growth assumptions after soft preliminary guidance. This comes despite sustained confidence in Hepzato uptake driven by positive CHOPIN trial data and improving profit margin expectations.Article d’analyse • Nov 21
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge
The Delcath Systems, Inc. ( NASDAQ:DCTH ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 06
Delcath: Temporary Headwinds Are No Cause For Concern
Summary Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time. Delcath's valuation is extremely low given the prospect of continued growth and strong margins once growth investments normalize. Read the full article on Seeking AlphaArticle d’analyse • Oct 28
The Delcath Systems, Inc. (NASDAQ:DCTH) Analysts Have Been Trimming Their Sales Forecasts
The latest analyst coverage could presage a bad day for Delcath Systems, Inc. ( NASDAQ:DCTH ), with the analysts making...Article d’analyse • Aug 09
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqCM:DCTH 1 Year Share Price vs Fair Value Explore Delcath Systems's Fair Values from the Community and select...Article d’analyse • Jul 12
Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 29% Share Price Plunge
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 29% in the last month, reversing a fair...Article d’analyse • Jun 18
Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Article d’analyse • May 22
Delcath Systems, Inc.'s (NASDAQ:DCTH) 52% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • May 11
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, Delcath Systems, Inc. ( NASDAQ:DCTH ) came out with a strong set of first-quarter numbers that could...
Nouveau récit • May 02
HEPZATO Launch And European Expansion Will Expand Treatment Access
Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.Article d’analyse • Mar 11
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have retraced a considerable 27% in the last month, reversing a fair...Article d’analyse • Jan 18
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Delcath Systems, Inc. ( NASDAQ:DCTH ) shareholders have had their patience rewarded with a 31% share price jump in the...Article d’analyse • Dec 19
Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Nov 18
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Summary Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors. Despite promising trends, investors should be cautious of seasonality impacts and the risks associated with upcoming Phase II trials and increased R&D expenses. I take a look at the charts to see if I can identify an opportunity to add to my position. Read the full article on Seeking AlphaArticle d’analyse • Nov 01
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Despite an already strong run, Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have been powering on, with a gain of 26...Article d’analyse • Sep 10
Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have continued their recent momentum with a 26% gain in the last month...Article d’analyse • Aug 27
Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Aug 07
Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Delcath Systems, Inc. ( NASDAQ:DCTH ) filed its quarterly result this time last...Rendement pour les actionnaires
| DCTH | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -3.5% | -5.5% | -0.9% |
| 1Y | 46.8% | -19.0% | 14.2% |
Rendement vs Industrie: DCTH a dépassé le secteur US Medical Equipment qui a rapporté -19 % au cours de l'année écoulée.
Rendement vs marché: DCTH a dépassé le marché US qui a rapporté 14.2 % au cours de l'année écoulée.
Volatilité des prix
| DCTH volatility | |
|---|---|
| DCTH Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: DCTH n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de DCTH ( 9% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1988 | 156 | Gerard Michel | www.delcath.com |
Delcath Systems, Inc. est une société d'oncologie interventionnelle qui se concentre sur le traitement des cancers du foie primaires et métastatiques aux États-Unis et en Europe. Le principal produit candidat de la société est HEPZATO KIT, un système d'administration de melphalan pour injection/hépatique qui permet d'administrer une chimiothérapie à haute dose dans le foie tout en contrôlant l'exposition systémique et les effets secondaires associés. Son programme de développement clinique pour HEPZATO est l'essai clinique FOCUS pour les patients atteints de mélanome uvéal métastatique à dominante hépatique afin d'étudier le taux de réponse objective dans le mélanome uvéal métastatique.
Delcath Systems, Inc. Résumé des fondamentaux
| DCTH statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$552.06m |
| Bénéfices(TTM) | US$532.00k |
| Recettes(TTM) | US$95.42m |
1,038x
Ratio P/E5.8x
Ratio P/SLe site DCTH est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| DCTH compte de résultat (TTM) | |
|---|---|
| Recettes | US$95.42m |
| Coût des recettes | US$12.36m |
| Marge brute | US$83.06m |
| Autres dépenses | US$82.53m |
| Les revenus | US$532.00k |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.015 |
| Marge brute | 87.05% |
| Marge bénéficiaire nette | 0.56% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de DCTH?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/13 02:27 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Delcath Systems, Inc. est couverte par 11 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |
| William Maughan | Canaccord Genuity |